#
0 likes1 view
Categories Politics

President Trump Announces Nine New Big Pharma “Most Favored Nation Status” Signees Today – HUGE Implications for Healthcare Costs!

December 19, 2025

Donald Trump delivers a speech at a podium with the presidential seal, flanked by officials in a formal setting.

Donald Trump delivers a speech at a podium with the presidential seal, flanked by officials in a formal setting.

 

Today, President Donald Trump announced the “Largest Development to Date in Bringing Most-Favored-Nation (MFN) Pricing to American Patients via the White House website and an Oval Office press conference.

The new agreements announced this afternoon include nine major pharmaceutical manufacturers, including Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi, and will help “reduce prices on drugs that treat numerous costly and chronic conditions, including type two diabetes, rheumatoid arthritis, multiple sclerosis, asthma, COPD, hepatitis B and C, HIV, and certain cancers,” according to the White House Fact Sheet.

The agreements will provide “every State Medicaid program in the country [with] access to MFN drug prices on products made by the nine companies” which will result in “billions of dollars in savings” to American taxpayers.

Today, during a press conference, President Trump announced the deal while highlighting that America has just 4% of the world’s population and we consume 13% of the world’s prescription drugs.  But, most shockingly, we account for 75% of Big Pharma’s profits.

That ends now.  And it is in part thanks to President Trump’s favorite word: tariffs.

The MFN will essentially require the Big Pharma powerhouses to sell their respective drugs in the United States for the lowest price offered in the other nations.

As an example, President Trump highlighted the price reduction of a blood thinner from Sanofi Pharmaceuticals that used to cost $750 now down to less than $16 and HIV medication from Bristol Myers Squibb that used to cost nearly $1500 down to $217.  He also announced that a hepatitis B medication will decrease from $1400 to $413.

Lastly, President Trump mentioned a hepatitis C medication from Gilead that previously cost from nearly $25,000 to less than $2,500.

The White House lists the following examples as well:

  • Amgen will reduce the price of its cholesterol-lowering drug Repatha from $573 to $239 for patients purchasing directly through TrumpRx.
  • Bristol Myers Squibb will reduce the price of its HIV medication, Reyataz, from $1,449 to $217 for patients purchasing directly through TrumpRx.
  • Boehringer Ingelheim will reduce the price of its type two diabetes medication, Jentadeuto, from $525 to $55 for patients purchasing directly through TrumpRx.
  • Genentech will reduce the price of its flu medication, Xofluza, from $168 to $50 for patients purchasing directly through TrumpRx.
  • Gilead Sciences will reduce the price of its Hepatitis C medication, Epclusa, from $24,920 to $2,425 for patients purchasing directly through TrumpRx.
  • GSK will reduce the prices of its inhaler portfolio. Prices for the popular asthma inhaler Advair Diskus 500/50 will fall from $265 to $89 for patients purchasing directly through TrumpRx.
  • Merck will reduce the price of its diabetes medication, Januvia, from $330 to $100 for patients purchasing directly through TrumpRx.
  • Novartis will reduce the price of its Multiple Sclerosis medication, Mayzent, from $9,987 to $1,137 for patients purchasing directly through TrumpRx.
  • Sanofi will reduce the price of its prescription blood thinner, Plavix, from $756 to $16 for patients purchasing directly through TrumpRx and Sanofi will list its insulin products at TrumpRx at $35 per month’s supply.

 

The President also announced that the pharmaceutical companies at the event will also invest over $150 billion in “domestic pharmaceutical manufacturing in America,” attributing the shift to tariffs.

While Democrats in Congress are melting down over the disappearing Affordable Care Act subsidies, President Trump has done more to reduce the cost of healthcare in the United States than any combination of Democrats or Republicans, combined, and in less than one year.

You can watch the entire press conference here:

 

The post President Trump Announces Nine New Big Pharma “Most Favored Nation Status” Signees Today – HUGE Implications for Healthcare Costs! appeared first on The Gateway Pundit.